Skip to main content
Premium Trial:

Request an Annual Quote

Counsyl Lays Off 27 Employees

NEW YORK (GenomeWeb) – Molecular diagnostic company Counsyl has laid off 27 people, or about 6 percent of its more than 400-employee workforce, the firm said today.

In a statement, CEO Ramji Srinivasan said that the firm made the decision in order to "structure the company around advancing our relationships with clinicians and medical providers." The 27 employees who were laid off worked in sales support, marketing, design, and engineering.

Srinivasan added that the firm is hiring for "targeted roles" that support the development of clinical relationships in "commercial sales and clinical marketing."

South San Francisco, California-based Counsyl offers next-generation sequencing-based carrier screening, noninvasive prenatal testing, and inherited cancer screening.

Srinivasan said in the statement that the layoffs are not a result of stagnant test growth and that the firm has "double-digit" growth in its carrier screening product, as well as "rapid uptake" of its NIPT and inherited cancer tests.

In January, Srinivasan told investors at the JP Morgan Healthcare conference in San Francisco that the company had tested more than 500,000 patients. At the time, he also said that Counsyl was "poised for expansion into new markets," such as the somatic cancer market, and that it was developing a liquid biopsy assay.

The company did not confirm whether the recent layoffs were related to a potential expansion into the somatic cancer market.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more